News
T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback